These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia. Holcomb K; Weinberg JM J Drugs Dermatol; 2006 Oct; 5(9):863-6. PubMed ID: 17039651 [TBL] [Abstract][Full Text] [Related]
23. Zoster sine herpete: it would be rash to ignore it. Kennedy PG Neurology; 2011 Feb; 76(5):416-7. PubMed ID: 21282588 [No Abstract] [Full Text] [Related]
24. Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX™) in Korean Adults. Choi WS; Choi JH; Choi JY; Eom JS; Kim SI; Pai H; Peck KR; Sohn JW; Cheong HJ J Korean Med Sci; 2016 Jan; 31(1):13-7. PubMed ID: 26770032 [TBL] [Abstract][Full Text] [Related]
25. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Macaladad N; Marcano T; Guzman M; Moya J; Jurado F; Thompson M; Meechan C; Li D; Schlienger K; Chan I; Sadoff J; Schödel F; Silber JL Vaccine; 2007 Mar; 25(11):2139-44. PubMed ID: 17250932 [TBL] [Abstract][Full Text] [Related]
26. An inverse correlation of VZV skin-test reaction, but not antibody, with severity of herpes zoster skin symptoms and zoster-associated pain. Asada H; Nagayama K; Okazaki A; Mori Y; Okuno Y; Takao Y; Miyazaki Y; Onishi F; Okeda M; Yano S; Kumihashi H; Gomi Y; Maeda K; Ishikawa T; Iso H; Yamanishi K; J Dermatol Sci; 2013 Mar; 69(3):243-9. PubMed ID: 23183011 [TBL] [Abstract][Full Text] [Related]
27. Prevalence of anti-varicella zoster IgG antibody in undergraduate students. Bhattarakosol P; Chantarabul S; Pittayathikhun K; Mung-mee V; Punnarugsa V Asian Pac J Allergy Immunol; 1996 Dec; 14(2):129-31. PubMed ID: 9177828 [TBL] [Abstract][Full Text] [Related]
34. Herpes zoster: mistaken for radiculopathy and back pain. Nair PA J Indian Med Assoc; 2012 Jun; 110(6):399. PubMed ID: 23360045 [TBL] [Abstract][Full Text] [Related]
35. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Civen R; Chaves SS; Jumaan A; Wu H; Mascola L; Gargiullo P; Seward JF Pediatr Infect Dis J; 2009 Nov; 28(11):954-9. PubMed ID: 19536039 [TBL] [Abstract][Full Text] [Related]
36. Risk of Herpes Zoster and Disseminated Varicella Zoster in Patients Taking Immunosuppressant Drugs at the Time of Zoster Vaccination. Cheetham TC; Marcy SM; Tseng HF; Sy LS; Liu IL; Bixler F; Baxter R; Donahue JG; Naleway AL; Jacobsen SJ Mayo Clin Proc; 2015 Jul; 90(7):865-73. PubMed ID: 26051268 [TBL] [Abstract][Full Text] [Related]
37. [Herpes zoster in old adults]. Lang PO; Belmin J; Michel JP Presse Med; 2009 Apr; 38(4):571-83. PubMed ID: 19028069 [TBL] [Abstract][Full Text] [Related]
38. Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States. Patel MS; Gebremariam A; Davis MM Infect Control Hosp Epidemiol; 2008 Dec; 29(12):1157-63. PubMed ID: 18999945 [TBL] [Abstract][Full Text] [Related]
39. Primary varicella and herpes zoster among HIV-infected children from 1989 to 2006. Wood SM; Shah SS; Steenhoff AP; Rutstein RM Pediatrics; 2008 Jan; 121(1):e150-6. PubMed ID: 18086820 [TBL] [Abstract][Full Text] [Related]
40. Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009. Weinmann S; Chun C; Schmid DS; Roberts M; Vandermeer M; Riedlinger K; Bialek SR; Marin M J Infect Dis; 2013 Dec; 208(11):1859-68. PubMed ID: 23922376 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]